Who are LimmaTech Biologics's investors?

LimmaTech Biologics's investors include Adjuvant Capital, Andera Partners, Tenmile.

How much funding has LimmaTech Biologics raised?

LimmaTech Biologics has disclosed $3M raised across 1 of its 2 known rounds.

LimmaTech Biologics

Founded 2015 · 57 employees on LinkedIn · 5 known investors

LimmaTech Biologics develops vaccines targeting antimicrobial-resistant pathogens using a proprietary self-adjuvanting, multi-antigen vaccine platform along with disease-specific approaches. The company focuses on preventing increasingly untreatable microbial infections.

Biotech Healthtech

Investors · 5

Adjuvant CapitalNew York · $10M – $25M

Andera PartnersParis

Tenmile

Also in the syndicate · 2

AXA IM AltsleadNovo Holdings REPAIR Impact Fundlead

Funding

SEC filings, press & company announcements

$3M disclosed across 1 of 2 rounds · 2023–2024

$3MSeries AFeb 2024 · 2 sources
Adjuvant Capital (lead), AXA IM Alts (lead), Novo Holdings REPAIR Impact Fund (lead), Tenmile
Source ↗
Undisclosed amountSeries AOct 2023
Source ↗

Source: company announcements and press reports — follow each round's link for the claim.

In the news

LimmaTech Biologics to be Acquired by Lilly for Next-generation Vaccines Against Common Bacterial Infections - BioSpacebiospace.com · May 2026

LimmaTech Biologics to be Acquired by Lilly for Next-generation Vaccines Against Common Bacterial Infectionsbusinesswire.com · May 2026

LimmaTech Vaccinates First Participants in Phase 1 Study of Staphylococcus aureus Vaccine Candidate LBT-SA7finance.yahoo.com · Feb 2025

LimmaTech secures funding for vaccine technology developmentpharmaceutical-technology.com · Feb 2024

LimmaTech Biologics Adds Additional $3 Million in Series A Second Closing Bringing Total Raised to $40 Million - BioSpacebiospace.com · Feb 2024

LimmaTech Biologics Raises $37 Million Series A to Advance Its Pipeline of Vaccines Against Multidrug-Resistant Bacterial Infectionsbusinesswire.com · Oct 2023

Frequently asked questions

What does LimmaTech Biologics do?: LimmaTech Biologics develops vaccines targeting antimicrobial-resistant pathogens using a proprietary self-adjuvanting, multi-antigen vaccine platform along with disease-specific approaches. The company focuses on preventing increasingly untreatable microbial infections.
Who are LimmaTech Biologics's investors?: LimmaTech Biologics's investors include Adjuvant Capital, Andera Partners, Tenmile.
How much funding has LimmaTech Biologics raised?: LimmaTech Biologics has disclosed $3M raised across 1 of its 2 known rounds.